Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bacterial decolonization to prevent radiation dermatitis
NCT03883828Phase 3Completed
- Sponsor
- Montefiore Medical Center
- Start
- Jun 2019
- Primary completion
- Dec 2021
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mupirocin and chlorhexidine in radiation dermatitis (2 arms), sponsored by Montefiore Medical Center. Primary endpoints: Number of Participants With Incidence of High Grade Radiation Dermatitis at 8 weeks and Median Change in Quality of Life Scoring Rated by the Skindex-16 Dermatological Survey at 8 weeks. Started Jun 2019; status: completed.
02
Drugs
mupirocinchlorhexidine
03
Conditions
radiation dermatitis
Beyond the preview
Go deeper on NCT03883828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03883828.